Last update 20 Nov 2026

Midostaurin

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
4'-N-benzoylstaurosporine, 4-N-benzoyl staurosporine, Benzoylstaurosporine
+ [15]
Action
inhibitors, antagonists
Mechanism
FLT3 inhibitors(Tyrosine-protein kinase receptor FLT3 inhibitors), PKC inhibitors(Protein kinase C inhibitors), Syk inhibitors(Spleen tyrosine kinase inhibitors)
Originator Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
United States (28 Apr 2017),
RegulationBreakthrough Therapy (United States), Fast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), Orphan Drug (Japan), Orphan Drug (South Korea)
Login to view timeline

Structure/Sequence

Molecular FormulaC35H30N4O4
InChIKeyBMGQWWVMWDBQGC-IIFHNQTCSA-N
CAS Registry120685-11-2

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Aggressive Systemic Mastocytosis
South Korea
14 Feb 2019
FLT3 positive Acute Myeloid Leukemia
European Union
18 Sep 2017
FLT3 positive Acute Myeloid Leukemia
Iceland
18 Sep 2017
FLT3 positive Acute Myeloid Leukemia
Liechtenstein
18 Sep 2017
FLT3 positive Acute Myeloid Leukemia
Norway
18 Sep 2017
Mast-Cell Leukemia
European Union
18 Sep 2017
Mast-Cell Leukemia
Iceland
18 Sep 2017
Mast-Cell Leukemia
Liechtenstein
18 Sep 2017
Mast-Cell Leukemia
Norway
18 Sep 2017
Acute Myeloid Leukemia
United States
28 Apr 2017
Systemic Mastocytosis
United States
28 Apr 2017
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute Myeloid Leukemia with Myelodysplasia-Related ChangesPhase 3
Bulgaria
13 Feb 2018
Acute Myeloid Leukemia with Myelodysplasia-Related ChangesPhase 3
Croatia
13 Feb 2018
Acute Myeloid Leukemia with Myelodysplasia-Related ChangesPhase 3
Czechia
13 Feb 2018
Acute Myeloid Leukemia with Myelodysplasia-Related ChangesPhase 3
Estonia
13 Feb 2018
Acute Myeloid Leukemia with Myelodysplasia-Related ChangesPhase 3
Finland
13 Feb 2018
Acute Myeloid Leukemia with Myelodysplasia-Related ChangesPhase 3
France
13 Feb 2018
Acute Myeloid Leukemia with Myelodysplasia-Related ChangesPhase 3
Hungary
13 Feb 2018
Acute Myeloid Leukemia with Myelodysplasia-Related ChangesPhase 3
Italy
13 Feb 2018
Acute Myeloid Leukemia with Myelodysplasia-Related ChangesPhase 3
Lithuania
13 Feb 2018
Acute Myeloid Leukemia with Myelodysplasia-Related ChangesPhase 3
Norway
13 Feb 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
439
intensive induction chemotherapy
(East Asian)
oahmbeyyxj(fsbamxshpb) = hxvgvpceea eammvsgviy (tyrkkovwzs )
Positive
12 Dec 2026
intensive induction chemotherapy
(underrepresented racial/ethnic groups)
oahmbeyyxj(fsbamxshpb) = jvkppyypxt eammvsgviy (tyrkkovwzs )
Not Applicable
854
Midostaurin+intensive induction chemotherapy
cbbtjnndkx(imlfkvjxig) = lqnzfiyphw gumjorfuju (aukxesgvpg )
Positive
12 Dec 2026
Gilteritinib+intensive induction chemotherapy
cbbtjnndkx(imlfkvjxig) = poylkctmtl gumjorfuju (aukxesgvpg )
Not Applicable
1,031
szrxvfnntj(ntnmugbueb) = Post-induction adverse events were similar between cohorts for heart failure (18% vs 25%; RR 0.72, 95% CI 0.49-1.07) and sepsis (35.4% vs 34.3%; RR 1.03, 95% CI 0.77 - 1.38). Acute kidney injury was more frequent in IC (43.5% vs 29.2%; RR 1.49, 95% CI 1.08-2.06). rtsvcjpqjj (hanohoqezm )
Positive
12 Dec 2026
Not Applicable
881
uoyfuuixge(dkbhbvyljy) = clbgereqor szfwtdbsbq (pebzthklqs )
Positive
01 Aug 2026
uoyfuuixge(dkbhbvyljy) = endniovsys szfwtdbsbq (pebzthklqs )
Not Applicable
305
wzxownwcyx(anyjbhimne) = symjzroprc vjxvytmrls (gubpegakhi )
Positive
01 Aug 2026
wzxownwcyx(anyjbhimne) = zolyfnserv vjxvytmrls (gubpegakhi )
Phase 3
-
Midostaurin+chemotherapy
rusdzjvihl(syeyokziyq): HR = 0.78 (95.0% CI, 0.63 - 0.96)
Positive
29 May 2026
Quizartinib+chemotherapy
Not Applicable
215
Midostaurin+Intensive Chemotherapy
viwsfoytua(pugqtsvqvm) = zjqghnmowt cqtvyttmqn (adyvqtothn )
Positive
12 May 2026
Quizartinib+Intensive Chemotherapy
viwsfoytua(pugqtsvqvm) = fijlejjnlm cqtvyttmqn (adyvqtothn )
Not Applicable
Aggressive Systemic Mastocytosis
First line
elevated serum tryptase
125
zkelggpwju(mkpsdmyzek) = 7/46, 14% pts experienced a discontinuation syndrome after stopping midostaurin. The most commonly reported symptoms included fatigue, peripheral edema, pleural effusion, and diarrhea puvamhuctg (zqrstcnxlk )
-
14 May 2025
Phase 2
67
(Midostaurin: Part 1 (Japan Only))
cvxqwqqjef = tewhfbcrej tzjxlwovqb (jyhowaghws, pqffstnkoh - lxdqpccdvn)
-
11 Feb 2025
(Midostaurin: Part 2)
fpjgoqtciy(esepitqdgb) = harzxtwaod rppgdwhtne (xjquyizfwq, xbrxkfcylm - uqlxdewczz)
Not Applicable
-
dvqncosuxf(yvzrkpcmhv) = vhndpoegur fzibjpmjiv (poncvfikkh )
-
09 Dec 2024
dvqncosuxf(yvzrkpcmhv) = vwxbspkdlo fzibjpmjiv (poncvfikkh )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free